10.3 (REFILED) * PLEASE NOTE THAT CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT FILED WITH THE COMMISSION ALONG WITH THE INFORMATION REQUESTED TO BE OMITTED. OPTION AND LICENSE AGREEMENT 1....Option and License Agreement • January 14th, 2002 • Biokeys Pharmaceuticals Inc • Pharmaceutical preparations • California
EX-10.14 8 rare-ex1014_420.htm EX-10.14 ***Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under OPTION AND LICENSE AGREEMENTOption and License Agreement • May 5th, 2020 • New York
This OPTION AND LICENSE AGREEMENT (“Agreement”) is entered into as of March 10, 2015 (the “Execution Date”), with effectiveness as of February 18, 2014 (the “Effective Date”), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
EX-10.12 16 d317356dex1012.htm EX-10.12 CONFIDENTIAL TREATMENT REQUESTED OPTION AND LICENSE AGREEMENTOption and License Agreement • May 5th, 2020 • California
THIS OPTION AND LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of September 19, 2017 (the “Effective Date”), by and between ARCUS BIOSCIENCES, INC., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (“Arcus”), and TAIHO PHARMACEUTICAL CO., LTD., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (“TAIHO”).
Amendment No. 1 to Option and License AgreementOption and License Agreement • June 28th, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment”), effective as of June 23, 2020, amends certain provisions of the Option and License Agreement dated September 4, 2019, between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • June 28th, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
EX-10.19 25 d427310dex1019.htm EX-10.19 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. Execution Copy CONFIDENTIAL OPTION AND LICENSE AGREEMENTOption and License Agreement • May 5th, 2020 • New York
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made effective as of February 27, 2017 (the “Effective Date”), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (“Arsanis”).
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. OPTION AND LICENSE AGREEMENTOption and License Agreement • May 25th, 2010 • Furiex Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is effective as of the 15th day of December, 2006 (the “Effective Date”) by and among PHARMACO INVESTMENTS, INC., a Delaware corporation having a place of business at 3151 South Seventeenth Street, Wilmington, North Carolina 28412 (referred to hereinafter as “PII”), a wholly owned subsidiary of Pharmaceutical Product Development, Inc., a North Carolina corporation having its principal place of business at 3151 South 17th Street, Wilmington, NC 28412 (“PPD”), and RANBAXY LABORATORIES LTD., a corporation incorporated, organized and operating under the laws of India and having a place of business at Plot 90, Sector 32 Gurgaon 122001 (Haryana), India (hereinafter “RBX”). PII and RBX are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” PPD is a Party to this Agreement for the sole and limited purpose of agreeing to be bound by Section 12.19 of this Agreement.
EX-10.26 26 dex1026.htm OPTION AND LICENSE AGREEMENT, BIOGEN IDEC INTERNATIONAL GMBH Execution Copy Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. OPTION AND LICENSE...Option and License Agreement • May 5th, 2020 • Massachusetts
This Option and License Agreement, made this 18th day of March, 2009 (the “Effective Date”), is by and between AVEO Pharmaceuticals, Inc., a Delaware corporation, with principal offices located at 75 Sidney St., Cambridge, MA 02139 (“AVEO”) and Biogen Idec International GmbH, with principal offices located at Landis+Gyr-Strasse 3, 6300 Zug, Switzerland (“Biogen Idec”). Each of AVEO and Biogen Idec shall be referred to, individually, as a “Party”, and, collectively, as the “Parties”.
OPTION AND LICENCE AGREEMENTOption and License Agreement • April 8th, 2010 • Ontario
WHEREAS the Developer is planning to construct and install test wind towers (the “Towers”) and gather data from such Towers;
CONFIDENTIAL TREATMENT REQUESTED OPTION AND LICENSE AGREEMENTOption and License Agreement • September 16th, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances) • New York
This OPTION AND LICENSE AGREEMENT (“Agreement”) is entered into as of March 10, 2015 (the “Execution Date”), with effectiveness as of February 18, 2014 (the “Effective Date”), by and between REGENXBIO Inc., a limited liability company organized under the laws of the State of Delaware, with offices at 1701 Pennsylvania Avenue, NW, Suite 900, Washington, DC 20006 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, 4th Floor, Cambridge, MA 02139 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
OPTION AND LICENSE AGREEMENTOption and License Agreement • October 25th, 2013 • Xencor Inc • Pharmaceutical preparations
This OPTION AND LICENSE AGREEMENT (this “Agreement”), effective as of January 28, 2013 (the “Effective Date”), is made by and between Alexion Pharmaceuticals, Inc., a Delaware corporation (“Alexion”), having a principal place of business at 352 Knotter Drive, Cheshire, Connecticut 06410, and Xencor, Inc., a Delaware corporation (“Xencor”), having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016. Alexion and Xencor may each be referred to herein, individually, as a “Party” or, collectively, as the “Parties.”
Execution Version OPTION AND LICENSE AGREEMENTOption and License Agreement • May 5th, 2020 • New York
This Option and License Agreement is made as of March 21, 2016 (the “Execution Date”) by and between Aptose Biosciences Inc., a Canadian corporation having a place of business at 5955 Airport Road, Suite 228, Mississauga, Ontario, L4V 1R9, Canada (“Aptose”) and CrystalGenomics, Inc., a South Korean corporation having a place of business at 5th F. Bldg. A, Korea Bio Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea (“CG”). Aptose and CG are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
OPTION AND LICENSE AGREEMENTOption and License Agreement • January 12th, 2016 • Bavarian Nordic a/S / ADR • Biological products, (no disgnostic substances) • England
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into effective as of 03 March, 2015 (the “Effective Date”) by and among BAVARIAN NORDIC A/S, a Danish corporation having its principal place of business at Hejreskovvej 10A, DK-3490 Kvistgaard, Denmark (“BN”) and BAVARIAN NORDIC INC., BN’s wholly owned subsidiary, which is a Delaware corporation having its principal place of business at 2425 Garcia Avenue, Mountain View, CA 94043, USA (“BNInc”), on the one hand, and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 USA (“BMS”), on the other hand. BN and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. BNInc shall be considered a “Party” and one of the “Parties”, in each case jointly with BN, only with respect to the BNInc Provisions and shall have no other rights, obligations or liabilities under this Agreement other than as set out in the BNInc Provisions
OPTION AND LICENSE AGREEMENT (AGEN2373) by and between AGENUS INC. and GILEAD SCIENCES, INC. dated as of December 20, 2018Option and License Agreement • March 18th, 2019 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 20, 2018 (the “Execution Date”) by and between Agenus Inc., a Delaware corporation (“Agenus”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”). Agenus and Gilead are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
Option and License Agreement OPTION AND LICENSE AGREEMENT THIS OPTION AND LICENSE AGREEMENT (the "Agreement") is entered into as of 15th day of April, 2003 (the "Effective Date"), by and between Chemokine Therapeutics Corp., a Delaware corporation,...Option and License Agreement • August 2nd, 2004 • Chemokine Therapeutics Corp • North Carolina
Option and License AgreementOption and License Agreement • July 28th, 2020 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Option and License Agreement (this “Agreement”), effective as of June 9, 2020 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
Exhibit 10.2b June 29, 2000 University of Southern California University Park Los Angeles, CA 90089 Ladies and Gentlemen: Reference is made to (1) that certain Option and License Agreement, dated as of March 12, 1998, by and among University of...Option and License Agreement • March 30th, 2001 • Rubicon Medical Inc • Services-commercial physical & biological research
OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, A.G. March 4, 2022Option and License Agreement • March 7th, 2023 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of March 4, 2022(the “Effective Date”), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 (“Voyager”), and Novartis Pharma AG, a corporation, having its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Voyager and Novartis are referred to herein individually as a “Party” and collectively as the “Parties”.
OPTION AND LICENSE AGREEMENTOption and License Agreement • June 17th, 2016 • Cempra, Inc. • Pharmaceutical preparations • Delaware
This OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of January 29, 2016 (the “Effective Date”) by and between Cempra Pharmaceuticals, Inc., a Delaware corporation having an address at 6320 Quadrangle Dr. #360, Chapel Hill, NC 27517 (“Cempra”), and Macrolide Pharmaceuticals, Inc., a Delaware corporation having an address at 480 Arsenal St., Suite 130, Watertown, MA 02472 (“MP”). MP and Cempra may be referred to herein individually as a “Party” or collectively, as the “Parties.”
AMENDMENT Dated as of September 1, 1997Option and License Agreement • April 3rd, 1998 • Amerigon Inc • Motor vehicles & passenger car bodies
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OPTION AND...Option and License Agreement • May 17th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • New York
This Option and License Agreement (this “Agreement”), dated August 9, 2022 (the “Effective Date”), is entered into by and between Janssen Pharmaceutica NV, with its principal place of business at Turnhoutseweg 30, 2340 Beerse, Belgium (“Janssen”) and Precision Neuroscience NewCo, Inc., with its principal place of business at 29 Newbury Street, Boston, MA 02116, USA (“Licensee”). Janssen and Licensee are referred to herein individually as a “Party” and collectively as the “Parties.”
Option and Licence AgreementOption and License Agreement • November 24th, 2010 • Quark Pharmaceuticals Inc • Pharmaceutical preparations
Atugen AG, a company incorporated under the laws of Germany, whose registered office is at Robert-Rössle-Str. 10, D13125 Berlin, Germany of the first Part;
VALIDIVE® OPTION AND LICENSE AGREEMENT BY AND BETWEEN MONOPAR THERAPEUTICS INC. AND ONXEO S.A.Option and License Agreement • August 15th, 2019 • Monopar Therapeutics • Pharmaceutical preparations • New York
THIS OPTION AND LICENSE AGREEMENT (together with any Schedules attached hereto, this “Agreement”) is made and entered into as of June 17, 2016 (the “Effective Date”), by and between Monopar Therapeutics Inc., a Delaware corporation located at 598 Rockefeller Rd, Lake Forest, Illinois 60201, United States of America (“Monopar”), and Onxeo S.A., a French société anonyme à Conseil d’administration located at 49, boulevard du Général Martial Valin, 75015 Paris, France (“Onxeo”). Monopar and Onxeo are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
OPTION AND LICENSE AGREEMENTOption and License Agreement • October 3rd, 2022 • Yumanity Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Option and License Agreement (the “Agreement”) is made and entered into effective as of August 10, 2020 (the “Effective Date”), by and between GigaGen, Inc., a Delaware corporation (“GigaGen”), having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080, and Kineta, Inc., a Washington corporation (“Kineta”), having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109. GigaGen and Kineta are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,...Option and License Agreement • April 27th, 2018 • Scholar Rock Holding Corp • Biological products, (no disgnostic substances) • New York
THIS OPTION AND LICENSE AGREEMENT (this “Agreement”) is dated as of December 17, 2013 (the “Effective Date”) by and between Scholar Rock, Inc., a Delaware company having its principal place of business at 300 Third St., 4th Floor, Cambridge, MA 02142 (“Scholar Rock”), and Janssen Biotech, Inc., a Pennsylvania corporation having its principal place of business at 800/850 Ridgeview Drive, Horsham, PA 19044 (“JBI”). Scholar Rock and JBI are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
OPTION AND LICENSE AGREEMENTOption and License Agreement • July 18th, 2005 • Warner Chilcott CORP • New York
This OPTION AND LICENSE AGREEMENT (this “Agreement”), dated as of March 24, 2004 (the “Effective Date”), is made by and between Barr Laboratories, Inc., a corporation organized and existing under the laws of Delaware (“Barr”), and Galen (Chemicals) Limited, a company organized and existing under the laws of the Republic of Ireland (“Galen”). Barr and Galen are each sometimes referred to individually as a “Party” and together as the “Parties.”
ContractOption and License Agreement • September 3rd, 2008 • Adolor Corp • Pharmaceutical preparations • Pennsylvania
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as **. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
May 16th, 2019, Exelixis and Iconic Therapeutics enter into exclusive option, and license agreement for novel ADC, ICON-2 worth $7.5MOption and License Agreement • February 8th, 2023
December 2nd, 2020, Exelixis exercises option and in-licenses Iconic Therapeutics’ ICON-2 ahead of planned investigational new drug application for
Fourth AmendmentOption and License Agreement • June 8th, 2016 • Aptose Biosciences Inc. • Biological products, (no disgnostic substances)
This Amendment (the "Fourth Amendment") effective as of June 1, 2016 (the "Effective Date"), is entered into by and between CRYSTALGENOMICS, INC., a South Korean corporation having a place of business at 5th F. Bldg.A, Korea Bio Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea ("CG") and APTOSE BIOSCIENCES, INC., a Canadian corporation having a place of business at 5955 Airport Road, Suite 228, Mississauga, Ontario, L4V 1R9, Canada ("Aptose"). CG and Aptose are sometimes referred to herein individually as a "Party" and collectively as the "Parties".
OPTION AND LICENSE AGREEMENTOption and License Agreement • August 11th, 2020 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations • Delaware
This Option and License Agreement (the “Agreement”) is made and entered into effective as of June 17, 2020 (the “Effective Date”) by and between Alpine Immune Sciences Inc., a Delaware corporation having its principal place of business at 188 East Blaine St, Suite 200, Seattle, WA 98102, United States (“Licensor”), and AbbVie Ireland Unlimited Company, an Irish private unlimited company (“AbbVie”). Licensor and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Second AmendmentOption and License Agreement • June 8th, 2016 • Aptose Biosciences Inc. • Biological products, (no disgnostic substances)
This Amendment (the "Second Amendment") effective as of May 13, 2016 (the "Effective Date"), is entered into by and between CRYSTALGENOMICS, INC., a South Korean corporation having a place of business at 5th F. Bldg.A, Korea Bio Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea ("CG") and APTOSE BIOSCIENCES, INC., a Canadian corporation having a place of business at 5955 Airport Road, Suite 228, Mississauga, Ontario, L4V 1R9, Canada ("Aptose"). CG and Aptose are sometimes referred to herein individually as a "Party" and collectively as the "Parties".
AMENDMENT NO. 1 TO OPTION AND LICENSE AGREEMENTOption and License Agreement • November 8th, 2018 • Arcus Biosciences, Inc. • Pharmaceutical preparations • California
This Amendment No. 1 to the Option and License Agreement (this “Amendment”) is made and entered into effective as of September 1, 2018 (the “Amendment Effective Date”) by and between Arcus Biosciences, Inc., a company organized under the laws of State of Delaware, U.S.A., having a business address at 3928 Point Eden Way, Hayward, CA 94545, U.S.A. (“Arcus”), and TAIHO Pharmaceutical Co., Ltd., a corporation organized under the laws of Japan, having a business address at 1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan (“TAIHO”). Arcus and TAIHO are sometimes collectively referred to herein as the “Parties” and separately as a “Party.” Capitalized terms used herein but not defined herein shall have the meaning set forth in that certain Option and License Agreement made and entered into effective as of September 19, 2017, by and between Arcus and TAIHO (the “Agreement”).
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED AS [***].Option and License Agreement • August 11th, 2022 • Alpine Immune Sciences, Inc. • Pharmaceutical preparations
This letter serves to memorialize the agreement between AbbVie and Alpine to replace Schedule 1.157 of the Agreement with the Schedule 1.157 attached to this letter as Exhibit A.
THIRD AMENDMENT TO OPTION AND LICENSE AGREEMENTOption and License Agreement • May 30th, 2023 • Kineta, Inc./De • Pharmaceutical preparations
This Third Amendment to Option and License Agreement (the “Amendment”), effective as of May 25, 2023 (the “Third Amendment Effective Date”) by and between GigaGen, Inc., a Delaware corporation having a place of business at 1 Tower Place, Suite 750, South San Francisco, CA 94080 (“GigaGen”) and Kineta, Inc., a Delaware corporation having a place of business at 219 Terry Avenue North, Suite 300, Seattle, WA 98109 on behalf of itself and its Affiliates (“Kineta”), amends that certain Option and License Agreement, dated June 9, 2021 by and between GigaGen and Kineta as amended by that certain First Amendment to Option and License Agreement, dated July 31, 2022 as further amended by the certain Second Amendment to Option and License Agreement, dated December 21, 2022 (together, the “Agreement”). Each of GigaGen and Kineta shall be referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms not defined herein shall have the same meanings as set forth in
FIRST AMENDMENT TO OPTION and License AgreementOption and License Agreement • May 7th, 2019 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations
This FIRST AMENDMENT TO OPTION AND LICENSE AGREEMENT (“First Amendment”) is entered into as of March 18, 2019 (“First Amendment Effective Date”) by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 (“Licensor”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 840 Memorial Drive, Cambridge, MA 02139 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
